Athens LifeTech Park is incorporated as a stand alone, not-for-profit entity (AMKE) and its operation is overseen by an independent Board of Directors.
Chairman of the Board
Board Member
Board Member
Board Member
Kleanthis G. Xanthopoulos, PhD., is a recognized biotechnology executive, serial entrepreneur, and investor with a strong track record in founding and leading innovative life sciences companies. He has founded five companies, taken three life science companies public on Nasdaq as CEO, and financed and brokered numerous creative multibillion-dollar strategic alliances and partnership deals with large pharmaceutical partners.
Dr. Xanthopoulos serves as an advisor and Chairman of Stork Capital Life Sciences, a multinational fund, a position he has held since 2020. He was the Chairman and CEO of Shoreline Biosciences until its acquisition by Concentra in 2025. Previously, he served as President and CEO of IRRAS Inc., a Managing General Partner at Cerus DMCC, a global investment firm, and President and CEO of Regulus Therapeutics Inc. from 2007 to 2015. Dr. Xanthopoulos built a unique foundation that ultimately led to the acquisition of the company by Novartis. He was also Managing Director at Enterprise Partners Venture Capital (2006–2007). Earlier, he co-founded and was President & CEO of Anadys Pharmaceuticals (acquired by Roche). Dr. Xanthopoulos was a Vice President at Aurora Biosciences (1997–2000), acquired by Vertex Pharmaceuticals. He is Chairman of the board of Sente Inc., a private commercial-stage cosmeceutical company he co-founded in 2007. His scientific credentials include serving as a Section Head at the National Human Genome Research Institute (NIH) from 1995 to 1997, contributing to the Human Genome Project, and holding an associate professorship at the Karolinska Institute in Stockholm.
Dr. Xanthopoulos is an Onassis Foundation Scholar and has received several honors, including the E&Y Entrepreneur of the Year (San Diego, 2006), San Diego Business Journal CEO of the Year (2013), and the Argo Innovation Award (2025). He holds a B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and both an M.Sc. in Microbiology and a Ph.D. in Molecular Biology from the University of Stockholm, Sweden. He is married and has four adult children.
Eleni Pentafragka, LLB, MSc, is the Chief Strategy Officer and a Board Member at ELPEN, leading innovation strategy while overseeing legal and corporate affairs and HR. She is the Executive Vice Chair of Athens LifeTech Park, Greece's first biotechnology park and the first of its kind in SE Europe.
She serves on the Innovation Committee of the Hellenic Federation of Enterprises (SEV), where she previously led the Health & Life Sciences Working Group, and is a Board Member at Medicines for Europe.
With a background in law (Athens Kapodistrian), international business (DEREE), and international health policy (LSE), she is passionate about building the Greek and European biotech ecosystem, advancing biomedical innovation, and empowering women in leadership. Energized by bringing ambitious ideas to life through focus, collaboration, and meaningful execution.
Dimitris Agrafiotis, PhD, FRSC, is an accomplished scientific and technology leader with deep expertise at the convergence of digital innovation, data and computational sciences, and life sciences R&D. His career spans venture-backed biotechnology, global pharmaceutical organizations, and the healthcare services industry, driving impactful transformation across the full research and development continuum.
Dr. Agrafiotis is a Director at Arsenal Capital Partners, where he leads digital, data, and AI strategy for the firm’s healthcare portfolio. Prior to joining Arsenal, he served as Chief Digital Officer at Generate Biomedicines; Vice President of Digital for Worldwide Research, Development and Medical at Pfizer; Chief Information Officer for the Novartis Institutes for Biomedical Research; Chief Data Officer and Head of Technology Products at Covance/LabCorp; and Vice President of Research and Early Development Informatics & IT at Johnson & Johnson. Earlier, he held senior scientific roles at Parke-Davis and played a key role in the growth and IPO of 3-Dimensional Pharmaceuticals, later acquired by J&J.
Dr. Agrafiotis holds a B.S. in Chemistry from the University of Patras and a Ph.D. in Theoretical Chemistry from Imperial College London, followed by postdoctoral research at the University of California, Berkeley and Harvard University, where he trained under Nobel Laureate E.J. Corey.
He is the author of more than 100 peer-reviewed publications and book chapters, holds 18 issued U.S. patents, and ranks among the top 1% of most-cited scientists globally. His achievements have been recognized through numerous honors, including his election as Fellow of the Royal Society of Chemistry in 2012 and selection for Computerworld’s Premier 100 Technology Leaders in 2016 for his impact in technology and innovation leadership.
Konstantina (“Tina”) Katcheves, MSc., J.D., is an accomplished biopharmaceutical executive with a strong track record in corporate strategy, business development, and driving innovation-focused growth across the life sciences industry. She has led major strategic transactions, expanded global pipelines, and built high-performing organizations through cross-functional leadership and execution excellence.
Ms. Katcheves currently serves as Senior Vice President, Chief Business and Strategy Officer at Acadia Pharmaceuticals Inc., where she oversees business development and corporate strategy as a member of the Executive Leadership Team. She joined Acadia following her role as Senior Vice President, Global Business Development at Teva Pharmaceuticals, where she shaped Teva’s innovative medicines strategy and strengthened long-term portfolio capabilities.
Prior to Teva, Ms. Katcheves held senior executive roles at Bristol Myers Squibb, including Interim Head of Enterprise Strategy and Business Development. During her tenure, she led significant transactions such as the US$14 billion acquisition of Karuna Therapeutics and contributed to more than US$18 billion in announced deals advancing both revenue and pipeline innovation. Earlier in her career, she held strategic leadership positions at Agilent Technologies and Lonza Group, gaining broad expertise across healthcare and life sciences.
Ms. Katcheves holds an Master of Science in Biotechnology from Johns Hopkins University, a Juris Doctor from the University of Oklahoma School of Law, and a Bachelor of Science in Biochemistry and Cell Biology from the University of California, San Diego.
Dimitris Tryfon is a business executive and investor with leadership experience in the pharmaceutical industry and diversified investment activities in Greece and internationally. His professional focus spans healthcare, venture capital, private equity, and real estate, while he remains actively engaged in cultural initiatives.
Mr. Tryfon serves as Executive President of Winmedica S.A., a leading Greek pharmaceutical company within the ELPEN Group, employing more than 200 people and generating annual turnover exceeding €120 million. Winmedica is active across the prescription, hospital, and specialty medicines markets, contributing to strengthened access to high-quality therapies.
He is also Founder and Partner of T-Life Capital, a family investment office with activities in venture capital, private equity, and real estate. In addition, he serves as a Board Member of ELPEN and Ble Kedros S.A., a publicly listed Real Estate Investment Trust.
Beyond his business responsibilities, Mr. Tryfon is the Founder of the Molyvos International Music Festival, an annual classical music event in Molyvos, Lesbos, supporting cultural development and emerging artistic talent.
Mr. Tryfon was born in Athens, Greece, in 1992.
Ελληνικά
English